Publications by authors named "Masaki Katayama"
TA 51-year-old Japanese man presented with a history of percutaneous transhepatic portal veinembolization, right hepatic lobectomy for hepatocellular carcinoma, and left upper pulmonary lobectomy forpulmonary metastasis of hepatocellular carcinoma. Owing to the elevated tumor marker levels,ultrasonography and fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PETCT) were performed, which revealed a left renal tumor 24 mm in diameter with FDG accumulation ;accordingly, renal metastasis of hepatocellular carcinoma was diagnosed. Localized radiofrequencyablation (RFA) was scheduled due to the absence of metastases other than that in the left kidney.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates how different biological and targeted synthetic anti-rheumatic drugs (b/tsDMARDs) affect kidney function in patients with rheumatoid arthritis (RA), particularly focusing on the incidence of chronic kidney disease (CKD).
- - Researchers followed 2,187 patients and evaluated the effects of tumor necrosis factor inhibitors (TNFi), cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig), interleukin-6 receptor inhibitors (IL-6Ri), and Janus kinase inhibitors (JAKi) on kidney health. They found that TNFi was linked to a lower CKD risk, while JAKi was associated with a higher risk.
- - The findings suggest that
Purpose: In Japan, immunohistochemistry for mismatch repair (MMR) proteins targeted at stage II and III colorectal cancers (CRCs) has been covered by national insurance since October, 2022. This study aimed to clarify the long-term outcomes of patients with stage II and III CRCs receiving postoperative adjuvant chemotherapy based on their MMR status.
Methods: The outcomes of 640 patients who underwent radical surgery for stage II and III CRCs were analyzed retrospectively.
Objectives: To investigate the predictive factors for difficult-to-treat rheumatoid arthritis (D2T RA) and assess the efficacy of biologic DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi).
Methods: Retrospective analysis was conducted on data from the ANSWER cohort comprising 3623 RA patients treated with bDMARDs or JAKi in Japan. Multivariate Cox proportional hazards modelling was used to analyse the hazard ratios (HRs) for treatment retention.
In selected patients with metastatic renal cell carcinoma, metastasectomy can achieve prolonged survival. Herein we report a patient with concomitant pancreatic and duodenal metastases occurring 12 years after total right nephrectomy for a renal cell carcinoma. The metastases were successfully treated by a pancreas-sparing duodenectomy and distal pancreatectomy.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore how large joint involvement (LJI) impacts disease activity and medication retention in rheumatoid arthritis (RA) patients starting biological therapies or Janus kinase inhibitors.
- Researchers analyzed data from 1721 patients, finding that LJI led to significant improvements in disease activity at 24 weeks, but patients with LJI had higher overall disease activity levels.
- Although drug retention rates were similar between patients with and without LJI, the findings suggest that early treatment strategies, particularly using interleukin-6 receptor inhibitors, could benefit those with LJI.
Article Synopsis
- A multicentre, retrospective study analyzed the retention rates and reasons for stopping treatment in elderly patients with rheumatoid arthritis (EORA), comparing Janus kinase inhibitors (JAKi) to biologic disease-modifying drugs.
- The study found that IL-6 inhibitors had better retention rates than TNF inhibitors, while JAKi showed lower discontinuation due to ineffectiveness but higher rates of discontinuation due to adverse events compared to TNF inhibitors.
- The conclusions suggest that while IL-6i and JAKi are effective for EORA patients, the increased risk associated with JAKi requires careful consideration and a tailored treatment approach.
Objectives: The objective of this study was to examine the effectiveness and drug tolerability of biological DMARD (bDMARD) and Janus kinase inhibitor (JAKi) monotherapy in patients with RA in a multicentre cohort study.
Methods: Patients with RA for whom bDMARD/JAKi monotherapy without conventional synthetic DMARDs has been initiated were included. Monotherapy regimens were categorized as IL-6 receptor inhibitors (IL-6Ris), cytotoxic T-lymphocyte-associated protein 4 immunoglobulin (CTLA4Ig), JAKis, or TNF inhibitors (TNFis).
Article Synopsis
- This study evaluated the effectiveness and safety of four JAK inhibitors (tofacitinib, baricitinib, peficitinib, and upadacitinib) in treating rheumatoid arthritis in a real-world setting, focusing on reducing bias and adjusting for patient characteristics.
- A total of 622 patients were analyzed, with no significant differences found in retention rates, disease activity scores, or remission rates among the various treatment groups after 6 months.
- Key predictive factors for treatment efficacy included baseline disease activity and previous treatment history, but overall, the four drugs showed similar effectiveness and safety in managing rheumatoid arthritis.
Article Synopsis
- The prognosis for patients with post-COVID-19 interstitial lung disease is still uncertain.
- An autopsy case is presented where the disease progressed to an acute exacerbation, resulting in death.
- Findings showed signs of both acute damage and severe fibrotic changes, confirming the seriousness of the post-COVID-19 lung condition.
Objectives: This multicentre retrospective study in Japan aimed to assess the retention of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors (JAKi), and to clarify the factors affecting their retention in a real-world cohort of patients with rheumatoid arthritis.
Methods: The study included 6666 treatment courses (bDMARD-naïve or JAKi-naïve cases, 55.4%; tumour necrosis factor inhibitors (TNFi) = 3577; anti-interleukin-6 receptor antibodies (aIL-6R) = 1497; cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) = 1139; JAKi=453 cases).
Objectives: Anaemia, a common comorbidity of RA, is related to high disease activity and poor prognosis. It is unknown which biologic/targeted synthetic (b/ts)-DMARDs are optimal for patients with anaemia and RA in regulating anaemia and controlling disease activity.
Methods: We investigated the change in haemoglobin (Hb) levels, drug retention rates and disease activities after the administration of b/ts-DMARDs with different modes of action [TNF inhibitors (TNFis), immunoglobulin fused with cytotoxic T-lymphocyte antigen (CTLA-4-Ig), IL-6 receptor inhibitors (IL-6Ris) and Janus kinase inhibitors (JAKis)] in patients with RA stratified by baseline Hb levels using the multicentre observational registry for patients with RA in Japan (ANSWER cohort).
This multicenter retrospective study aimed to clarify the prognostic factors for mortality and changes in treatment modalities and disease activities after the onset of pneumonia (PCP) in patients with rheumatoid arthritis (RA). Data regarding the clinical background, treatment modalities, and disease activity indicators of RA at the onset of PCP (baseline), and 6 months and 12 months after treatment were extracted. Of the 37 patients with RA-PCP (median age, 69 years; 73% female), chemical prophylaxis was administered to 8.
View Article and Find Full Text PDFThe aim of this multi-centre retrospective study was to clarify the prognostic factors for respiratory-related death in patients with interstitial lung disease (ILD) complicated rheumatoid arthritis (RA). Patient background data, treatment regimen, and disease activity indicators of RA and ILD at baseline, 6 months after the diagnosis of ILD, and at the last follow-up visit were extracted. A total of 312 patients with RA-ILD (17 patients who died from respiratory-related causes and 295 survivors) were included.
View Article and Find Full Text PDFObjectives: This multicenter, retrospective study evaluated the effectiveness of add-on methotrexate (MTX) or iguratimod (IGU) in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors (JAKis).
Methods: Forty-five patients were treated with new additional MTX (n = 22) or IGU (n = 23) and followed for 6 months. Patients' background is as follows: age, 59.
Article Synopsis
- Rheumatoid factor (RF) can bind to the Fc portion of anti-TNF inhibitors, potentially reducing their effectiveness in treating rheumatoid arthritis (RA).
- A study using data from the Kansai Consortium analyzed the therapeutic efficacy of two types of TNF inhibitors—those with Fc and those without Fc—among RA patients classified by RF titres.
- Results showed that patients treated with TNFi without Fc experienced a significantly lower disease activity score (DAS28-ESR) after 12 months compared to those treated with TNFi with Fc, indicating that TNFi without Fc may be more effective for RA patients with high RF levels.
Article Synopsis
- This study analyzed factors affecting the retention of Janus kinase inhibitors (JAKi) like baricitinib (BAR) and tofacitinib (TOF) in rheumatoid arthritis (RA) patients across multiple centers.
- It found that the main reasons for discontinuation were ineffectiveness (22.3%), toxic adverse events (13.3%), non-toxic reasons (7.2%), with no discontinuations due to remission.
- Key risk factors for discontinuation included a history of anti-IL-6R ineffectiveness, age (≥ 75 years), high doses of prednisone (≥ 5 mg/day), and being female; while prior treatments and the type of JAKi did not significantly impact discontinu
Objectives: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by localized and generalized bone loss. The risk of fractures is doubled in patients with RA. Denosumab, an anti-RANKL monoclonal antibody, is used for those with osteoporosis at high risk fracture and it has inhibitory effect of progressive bone erosion in patients with RA.
View Article and Find Full Text PDFObjective: We aimed to investigate the efficacy of anti-IL-6 receptor antibody (aIL-6) and other biologic disease-modifying antirheumatic drugs (bDMARDs), such as TNF inhibitor and CTLA4-Ig in the treatment of rheumatoid arthritis (RA) in patients with knee joint involvement.
Methods: We retrospectively analyzed 1059 treatment courses of patients with RA who visited our hospitals and were treated with bDMARDs. We categorized them into two groups, with or without knee joint involvement.
Background: This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of either tumor necrosis factor inhibitors (TNFi) or interleukin-6 inhibitors (IL-6i) in patients with elderly-onset rheumatoid arthritis (EORA).
Methods: Patients with rheumatoid arthritis (RA) enrolled in a Japanese multicenter observational registry between 2011 and 2020 were included. EORA was defined as RA with onset at 60 or over.
Objectives: The aim of this multicenter, retrospective study was to clarify the retention rates of sarilumab (SAR), baricitinib (BAR), and tofacitinib (TOF) in patients with rheumatoid arthritis (RA).
Methods: Patients treated with either SAR (n = 62), BAR (n = 166), or TOF (n = 185) (females, 80.9%; age, 61.
The objective of the study was to compare the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Patients with rheumatoid arthritis (RA) aged ≧18 years enrolled in a Japanese multicenter observational registry between 2009 and 2018 who had moderate or high disease activity when initiating bDMARDs were included. EORA was defined as RA with onset at 60 or over.
View Article and Find Full Text PDFBackground: This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in bDMARDs-naïve and bDMARDs-switched patients with rheumatoid arthritis (RA).
Methods: This study assessed 3897 patients and 4415 treatment courses with bDMARDs and TOF from 2001 to 2019 (2737 bDMARDs-naïve courses and 1678 bDMARDs-switched courses [59.5% of switched courses were their second agent], female 82.
Objectives: The aim of this multicenter, retrospective study was to clarify the retention of secondary biological disease-modifying antirheumatic drugs (bDMARDs) or Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA) who were primarily treated by tocilizumab (TCZ) or abatacept (ABT) as first bDMARDs.
Method: Patients who were treated by either TCZ (n = 145) or ABT (n = 76) and then switched to either tumor necrosis factor inhibitors (TNFi), TCZ, ABT, or JAKi (including only cases switched from TCZ) from 2001 to 2019 (female 81.0%, age 59.